IL6 and neoplasm: In cases without apparent mutations, the activation of the pathway in tumor cells often stems from an increase in factors that induce activation of the pathway’s upstream receptors—such as cytokines like IL-6, TNFα, and IL-1—within the tumor microenvironment [49].